Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 1;293(25):9736–9746. doi: 10.1074/jbc.RA117.001540

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

Figure 6. — Effect of the PfCDPK1 inhibitor purfalcamine on merozoites egress. Schizont-stage parasites (40–42 hpi) were treated with DMSO control, purfalcamine (500 nm, 1 μm, and 10 μm), or BAPTA-AM at 50 μm in duplicates and assayed for egress by flow cytometer. Data from two independent experiments (mean ± S.E.) showed a dose-dependent effect of purfalcamine on parasite egress. P, purfalcamine; B-AM, BAPTA-AM. Egress in the DMSO control was considered 100% for all experiments. The representative FACS raw data file shows loss of schizonts in the DMSO control, whereas the presence of stalled schizonts is seen in the presence of purfalcamine at 10 μm concentration. Inset, purfalcamine treatment abrogated the phosphorylation of PfSERA5 in schizont-stage parasites. Western blotting (WB) using anti-PfSERA5 serum shows a band at ∼50 kDa in DMSO-treated schizont extracts after pulldown using anti-phosphoserine–agarose, whereas no such band was visible in purfalcamine-treated parasite extracts.